PuSH - Publikationsserver des Helmholtz Zentrums München: Inducing differentiation of premalignant hepatic cells as a novel therapeutic strategy in hepatocarcinoma.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Wolf, B.* ; Krieg, K.* ; Falk, C.* ; Breuhahn, K.* ; Keppeler, H.* ; Biedermann, T.* ; Schmid, E.* ; Warmann, S.* ; Fuchs, J.* ; Vetter, S.* ; Thiele, D.* ; Nieser, M.* ; Avci-Adali, M.* ; Skokowa, Y.* ; Schöls, L.* ; Hauser, S.L.* ; Ringelhan, M. ; Yevsa, T.* ; Heikenwälder, M. ; Kossatz-Boehlert, U.*

Inducing differentiation of premalignant hepatic cells as a novel therapeutic strategy in hepatocarcinoma.

Cancer Res. 76, 5550-5561 (2016)

Verlagsversion

Postprint

DOI

PMC

	Open Access Green

Abstract
Metriken
Zusatzinfos

Hepatocellular carcinoma (HCC) represents the second leading cause of cancer-related deaths and is reported to be resistant to chemotherapy caused by tumor-initiating cells. These tumor-initiating cells express stem cell markers. An accumulation of tumor-initiating cells be found in 28-50% of all HCC and is correlated with a poor prognosis. Mechanisms that mediate chemoresistance include drug export, increased metabolism and quiescence. Importantly, the mechanisms that regulate quiescence in tumor-initiating cells have not been analyzed in detail so far. In the present research we have developed a single cell tracking method to follow up the fate of tumor-initiating cells during chemotherapy. Thereby, we were able to demonstrate that mCXCL1 exerts cellular state specific effects regulating the resistance to chemotherapeutics. mCXCL1 is the mouse homolog of the human Interleukin 8, a chemokine which correlates with poor prognosis in HCC patients. We found that mCXCL1 blocks differentiationof premalignant cells and activates quiescence in tumor-initiating cells. This process depends on the activation of the mTORC1 kinase. Blocking of the mTORC1 kinase induces differentiation of tumor-initiating cells and allows their subsequent depletion using the chemotherapeutic drug doxorubicin. Our work deciphers the mCXCL1-mTORC1 pathway as crucial in liver cancer stem cell maintenance and highlights it as a novel target in combination with conventional chemotherapy.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

8.556

1.921